test

Developmental Therapeutics

Maysa Abu-Khalaf MBBS, MD

Associate Professor of Medicine (Medical Oncology) and of Obstetrics, Gynecology, and Reproductive Sciences

Clinical Interests

Breast Cancer: Early and advanced stages, hormone receptor positive breast cancers, triple negative breast cancers, HER-2 positive breast cancers, adjuvant (postoperative) treatment, neoadjuvant (preoperative) treatment, metastatic breast cancer treatment, clinical trials. Gynecologic Cancers: Advanced/recurrent ovarian and endometrial cancers, clinical trials.


Board Certifications

2005
Medical Oncology, Board Certified

Patient Care Locations

maysa_abu-khalaffaculty-clinicsfalsetruetrue6truefalsefalse

Clinical Trials

ConditionsStudy Title
Breast Cancer (ER, PR, and HER2 negative), Colorectal Cancer, Endometrial Cancer, Gastric Adenocarcinoma, Glioblastoma Multiforme, Head/ Neck Squamous Cell Carcinoma, Melanoma, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Prostate Cancer, Brain and Nervous System, Breast - Female, Breast - Male, Colon, Lip, Oral Cavity and Pharynx, Lung, Melanoma, skin, Other Female Genital, Ovary, Prostate, Rectum, and StomachA Phase I/IIa, First Time in human, open-label dose-escalation study of GSK2636771 in subjects with advanced solid tumors with PTEN deficiency
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer, Other Female Genital, and OvaryChemotherapy Toxicity in Elderly Women with Ovarian, Primary Peritoneal or Fallopian Tube Cancer (GOG 0273)
Cancer, Breast - Female, and Breast - MalePhase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer (S1207)
Breast - Female and Breast - MaleA Randomized, Multicenter, Open-label Phase III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine versus Trastuzumab as Adjuvant Therapy for Patients with HER2-Positive Primary Breast Cancer who have Residual Tumor Present Pathologically in the Breast or Axillary Lymph Nodes following Preoperative Therapy (NSABP B50/Katherine Study)

Edit Profile